Skandinaviska Enskilda Banken (SEB)’s Genomic Health, Inc. GHDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-32,600
| Closed | -$2.21M | – | 982 |
|
|
2019
Q3 | $2.21M | Sell |
32,600
-11,600
| -26% | -$797K | 0.02% | 514 |
|
|
2019
Q2 | $2.57M | Buy |
44,200
+2,900
| +7% | +$172K | 0.02% | 445 |
|
|
2019
Q1 | $2.89M | Sell |
41,300
-600
| -1% | -$44.5K | 0.03% | 384 |
|
|
2018
Q4 | $2.7M | Sell |
41,900
-13,300
| -24% | -$932K | 0.02% | 392 |
|
|
2018
Q3 | $3.88M | Buy |
55,200
+5,900
| +12% | +$345K | 0.03% | 345 |
|
|
2018
Q2 | $2.48M | Sell |
49,300
-29,200
| -37% | -$1.16M | 0.02% | 387 |
|
|
2018
Q1 | $2.46M | Sell |
78,500
-12,400
| -14% | -$411K | 0.02% | 347 |
|
|
2017
Q4 | $3.11M | Sell |
90,900
-7,500
| -8% | -$239K | 0.03% | 352 |
|
|
2017
Q3 | $3.16M | Hold |
98,400
| – | – | 0.03% | 370 |
|
|
2017
Q2 | $3.2M | Sell |
98,400
-20,100
| -17% | -$637K | 0.03% | 371 |
|
|
2017
Q1 | $3.73M | Sell |
118,500
-4,200
| -3% | -$124K | 0.04% | 332 |
|
|
2016
Q4 | $3.61M | Sell |
122,700
-6,200
| -5% | -$189K | 0.04% | 286 |
|
|
2016
Q3 | $3.73M | Buy |
128,900
+66,900
| +108% | +$1.86M | 0.04% | 309 |
|
|
2016
Q2 | $1.6M | Buy |
62,000
+35,800
| +137% | +$951K | 0.02% | 507 |
|
|
2016
Q1 | $649K | Sell |
26,200
-49,400
| -65% | -$1.36M | 0.01% | 620 |
|
|
2015
Q4 | $2.66M | Buy |
+75,600
| New | +$2.02M | 0.03% | 317 |
|
Skandinaviska Enskilda Banken (SEB)'s GHDX Position: Q4 2019 in Review
Skandinaviska Enskilda Banken (SEB) sold out of Genomic Health, Inc. (GHDX) in Q4 2019, closing a stake of 32,600 shares — an estimated $2.21M sold.
Skandinaviska Enskilda Banken (SEB) first reported a position in GHDX in Q4 2015 and held it in 16 quarters. The position peaked at $3.88M in Q3 2018. 0 funds tracked by Wall St. Rank hold GHDX as of Q4 2019.
- Skandinaviska Enskilda Banken (SEB) reported no remaining Genomic Health, Inc. position as of Q4 2019 after selling out during the quarter.
- Skandinaviska Enskilda Banken (SEB) sold 32,600 Genomic Health, Inc. shares in Q4 2019, an estimated $2.21M.
- Skandinaviska Enskilda Banken (SEB) first reported a position in Genomic Health, Inc. in Q4 2015 and held it in 16 quarters.
- Skandinaviska Enskilda Banken (SEB)'s Genomic Health, Inc. position peaked at $3.88M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2019.
Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q4 2019, filed 14 Feb 2020.